Pharmacologic Therapies for Type 2 Diabetes

AbstractType 2 diabetes (T2D) is a complex chronic disorder with an increasing prevalence. Treatment of T2D involves both lifestyle and pharmacologic interventions aimed at lowering blood glucose levels to help counteract the negative effects of long-term hyperglycemia. The range of pharmacologic treatments for T2D has grown substantially, with newer agents demonstrating not only glucose-lowering efficacy, but also reductions in long-term cardiometabolic complications. This review discusses the newest pharmacologic agents for the treatment of T2D and the evidence regarding their cardiometabolic benefits. We highlight key considerations for their use based on patient characteristics and clinical context. In addition, we discuss emerging pharmacologic therapies that target the underlying pathogenesis of T2D, underscoring ongoing advances in diabetes care.

Authors

Institutions

Publication Details

Journal
NEJM Evidence
Published
2025-08-26
DOI
https://doi.org/10.1056/evidra2400265
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacologic Therapies for Type 2 Diabetes

Bryan Kuo, Josephine H. Li
NEJM Evidence
Diabetes Treatment and Management
article

Pharmacologic Therapies for Type 2 Diabetes

Bryan Kuo, Josephine H. Li
article en

Abstract

AbstractType 2 diabetes (T2D) is a complex chronic disorder with an increasing prevalence. Treatment of T2D involves both lifestyle and pharmacologic interventions aimed at lowering blood glucose levels to help counteract the negative effects of long-term hyperglycemia. The range of pharmacologic treatments for T2D has grown substantially, with newer agents demonstrating not only glucose-lowering efficacy, but also reductions in long-term cardiometabolic complications. This review discusses the newest pharmacologic agents for the treatment of T2D and the evidence regarding their cardiometabolic benefits. We highlight key considerations for their use based on patient characteristics and clinical context. In addition, we discuss emerging pharmacologic therapies that target the underlying pathogenesis of T2D, underscoring ongoing advances in diabetes care.

NEJM EvidenceVol. 4(9)
Harvard University (US), Massachusetts General Hospital (US)
Openalex Percentile: Top 70%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.